Brainstorm Cell Therapeutics, Inc. (BCLI)
1.123
-0.04
(-3.40%)
USD |
OTCM |
Aug 28, 16:00
Brainstorm Cell Therapeutics Free Cash Flow : -4.057M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.057M |
| March 31, 2026 | -6.664M |
| December 31, 2025 | -6.975M |
| September 30, 2025 | -7.283M |
| June 30, 2025 | -9.48M |
| March 31, 2025 | -7.661M |
| December 31, 2024 | -9.093M |
| September 30, 2024 | -11.33M |
| June 30, 2024 | -14.46M |
| March 31, 2024 | -19.55M |
| December 31, 2023 | -20.48M |
| September 30, 2023 | -21.84M |
| June 30, 2023 | -20.26M |
| March 31, 2023 | -19.64M |
| December 31, 2022 | -19.35M |
| September 30, 2022 | -20.24M |
| June 30, 2022 | -22.09M |
| March 31, 2022 | -21.29M |
| December 31, 2021 | -26.60M |
| September 30, 2021 | -28.86M |
| June 30, 2021 | -29.18M |
| March 31, 2021 | -29.53M |
| December 31, 2020 | -35.57M |
| September 30, 2020 | -31.38M |
| June 30, 2020 | -28.10M |
| Date | Value |
|---|---|
| March 31, 2020 | -25.92M |
| December 31, 2019 | -11.72M |
| September 30, 2019 | -11.93M |
| June 30, 2019 | -14.79M |
| March 31, 2019 | -11.42M |
| December 31, 2018 | -12.76M |
| September 30, 2018 | -11.92M |
| June 30, 2018 | -1.571M |
| March 31, 2018 | -3.073M |
| December 31, 2017 | -2.544M |
| September 30, 2017 | -0.75M |
| June 30, 2017 | -4.793M |
| March 31, 2017 | -4.596M |
| December 31, 2016 | -5.961M |
| September 30, 2016 | -6.066M |
| June 30, 2016 | -8.322M |
| March 31, 2016 | -8.523M |
| December 31, 2015 | -7.453M |
| September 30, 2015 | -8.219M |
| June 30, 2015 | -6.796M |
| March 31, 2015 | -6.10M |
| December 31, 2014 | -4.648M |
| September 30, 2014 | -4.193M |
| June 30, 2014 | -3.818M |
| March 31, 2014 | -3.957M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| NovelStem International Corp. | -0.2295M |
| Summit Therapeutics, Inc. | -458.40M |
| Kezar Life Sciences, Inc. | -42.03M |
| Protara Therapeutics, Inc. | -66.49M |
| Clene, Inc. | -16.00M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -0.895M |
| Cash from Financing (Quarterly) | 0.898M |
| Free Cash Flow Per Share (Quarterly) | -0.0811 |
| Free Cash Flow to Equity (Quarterly) | -0.781M |
| Free Cash Flow to Firm (Quarterly) | -0.653M |
| Free Cash Flow Yield | -32.75% |